In Brief: Endo Buys Somar; Neptune, Enzymotec Settle Dispute; FDA Prohibits Omega-3 Nutrient Claims

Endo buys Somar; Neptune, Enzymotec settle patent infringement; FDA prohibits omega-3 nutrient claims; “Sell through” for herbals ends in U.K.; C&D licenses Nutrition 21’s chromium picolinate; Arizona DXM bill and Iowa Select Herbs drug claims.